Ablynx Successfully Generates Nanobodies Against an Ion Channel and Announces New GPCR Programme

13-Jan-2010 - Belgium

Ablynx announced two significant advances achieved within its R&D portfolio. In the first, it has demonstrated the successful generation of functional Nanobodies against an ion channel. In the second, Ablynx has demonstrated in vivo proof-of-concept for a GPCR targeting stem cell mobilization programme. The target, CXCR4, is a validated chemokine receptor that plays an important role in cell movement, tumor growth and metastasis.

Ablynx has generated functional Nanobodies in the sub-nanomolar range, against an ion channel. The Nanobodies can block the ion channel function irrespective of whether it has been indirectly or directly activated. The ion channel drug class is technically very challenging and only a few functional research reagent monoclonal antibodies exist. Ion channels are highly relevant therapeutic targets especially in areas such as neuropathic pain, neurological disorders, inflammation and cardiovascular disorders.

Ablynx has successfully generated functional Nanobodies against the clinically validated chemokine receptor, CXCR4. Two types of Nanobody have been identified: highly potent antagonistic Nanobodies, as well as anti-CXCR4 Nanobodies with inverse agonist function. Ablynx has demonstrated in vivo proof-of-concept in a hematopoietic stem cell model. A single, intravenous administration of formatted anti-CXCR4 Nanobody resulted in rapid mobilization of stem cells in vivo. The antagonistic Nanobodies are now being further evaluated for their ability to mobilize hematopoietic stem cells in certain types of cancers.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous